SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000950170-23-066248
Filing Date
2023-11-28
Accepted
2023-11-28 09:00:28
Documents
14
Period of Report
2023-11-26
Items
Item 2.05: Cost Associated with Exit or Disposal Activities
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K cadl-20231126.htm   iXBRL 8-K 46553
2 EX-99.1 cadl-ex99_1.htm EX-99.1 29996
3 GRAPHIC img160460863_0.jpg GRAPHIC 26615
  Complete submission text file 0000950170-23-066248.txt   245656

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT cadl-20231126.xsd EX-101.SCH 2464
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT cadl-20231126_pre.xml EX-101.PRE 11445
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT cadl-20231126_lab.xml EX-101.LAB 15755
8 EXTRACTED XBRL INSTANCE DOCUMENT cadl-20231126_htm.xml XML 4884
Mailing Address 117 KENDRICK STREET SUITE 450 NEEDHAM MA 02494
Business Address 117 KENDRICK STREET SUITE 450 NEEDHAM MA 02494 617-916-5445
Candel Therapeutics, Inc. (Filer) CIK: 0001841387 (see all company filings)

IRS No.: 522214851 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40629 | Film No.: 231442037
SIC: 2836 Biological Products, (No Diagnostic Substances)